Press releases
Shionogi-ViiV Healthcare announces positive initial data from phase III study of dolutegravir-based regimen vs Atripla in HIV
Shionogi-ViiV Healthcare LLC today announced that initial results have been received from the Phase III SINGLE (ING114467) study of the investigational integrase inhibitor dolutegravir in treatment-naïve adults with HIV-1.
GSK and Theravance announce positive results from four pivotal phase III studies for once-daily LAMA/LABA (UMEC/VI) in COPD
GSK plc and Theravance, Inc. today announced the results of four pivotal phase III studies of investigational LAMA/LABA involving over 4,000 patients with chronic obstructive pulmonary disease (COPD).
GlaxoSmithKline concludes previously announced agreement in principle to resolve multiple investigations with US Government and numerous states
GSK today announced that it has reached an agreement with the US Government, multiple states and the District of Columbia to conclude the Company’s most significant ongoing Federal government investigations.
GSK sets 20 July for expiration of tender offer to acquire Human Genome Sciences
GlaxoSmithKline plc (LSE: GSK) today announced it has extended its tender offer to acquire all of the outstanding shares of Human Genome Sciences (NASDAQ: HGSI) for US$13.00 per share in cash to 5:00 p.m. New York City time on 20 July 2012.
GSK continues with tender offer to acquire all outstanding shares of Human Genome Sciences
GSK today confirmed that it has received a renewed invitation from Human Genome Sciences to participate in its strategic alternatives review process which started in April.
GSK receives FDA approval for MenHibrix
GSK plc announced today that the US FDA has approved the vaccine MenHibrix® [Meningococcal Groups C and Y and Haemophilus b Tetanus Toxoid Conjugate Vaccine].
Stiefel signs worldwide acquisition and license agreement for Toctino®
Stiefel, a GSK company, today announced that it has entered into a worldwide agreement to acquire Toctino (alitretinoin) from Basilea Pharmaceutica Ltd. (Basilea).
GSK announces new 52-week data from phase III study of once-weekly albiglutide in type 2 diabetes
Detailed findings from a Phase III study comparing the investigational GLP-1 receptor agonist albiglutide to Lispro, were presented today at the ADA Meeting in Philadelphia, USA.
GSK extends tender offer for all outstanding shares of Human Genome Sciences
GSK today announced it has extended its tender offer to acquire all of the outstanding shares of Human Genome Sciences for US$13.00 per share in cash to 5:00 pm New York City time on Friday 29 June 2012.
GSK and XenoPort receive FDA approval for Horizant® for postherpetic neuralgia
GlaxoSmithKline plc (GSK) and XenoPort, Inc. (Nasdaq: XNPT) announced today that the United States (US) Food and Drug Administration (FDA) has approvedHorizant® (gabapentin enacarbil) Extended-Release Tablets for the management of postherpetic neuralgia (PHN) in adults.
